Abstract:The World Health Organization has declared that the outbreak of coronavirus disease 2019(COVID-19)is a global pandemic.As mutations occurred in the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the global epidemic still needs further concern.Worryingly,the effectiveness and neutralizing activity of existing antibodies and vaccines against SARS-CoV-2 variants is declining.There is an urgent need to find an effective antiviral medication with broad-spectrum inhibitory effects on novel coronavirus mutant strains against the SARS-CoV-2 infection.Neutralizing antibodies play an important role in the prevention and treatment of COVID-19.The interaction of spike-receptor-binding domain(Spike-RBD)of SARS-CoV-2 and human angiotensin-converting enzyme 2(ACE2)is the first and critical step of SARS-CoV-2 infection.Hence,the SARS-CoV-2 Spike-RBD is a hot target for neutralizing antibodies development.Evusheld,the combination of Tixagevimab and Cilgavimab monoclonal antibodies(mAbs)targeting Spike-RBD exhibits neutralizing activity against BA.2.12.1,BA.4 and BA.5,which could be used as pre-exposure prophylaxis against SARS-CoV-2 infection.The nucleocapsid(N)protein is a conservative and high-abundance structural protein of SARS-CoV-2.The nCoV396 monoclonal antibody,isolated from the blood of convalescent COVID-19 patients against the N protein of SARS-CoV-2.This mAb not only showed neutralizing activity but also inhibits hyperactivation of complement and lung injury induced by N protein.The mAb 3E8 targeting ACE2 showed broadly neutralizing activity against SARS-CoV-2 and D614G,B.1.1.7,B.1.351,B.1.617.1 and P.1 variants in vitro and in vivo,but did not impact the biological activity of ACE2.Compared with neutralizing antibodies,small molecule inhibitors have several advantages,such as broad-spectrum inhibitory effect,low cost,and simple administration methods.Several small-molecule inhibitors disrupt viral binding by targeting the ACE2 and N-terminal domain(NTD)of SARS-CoV-2 spike protein.Known drugs such as chloroquine and hydroxychloroquine could also block the infection of SARS-CoV-2 by interacting with residue Lys353 in the peptidase domain of ACE2.The transmembrane protease serine 2(TMPRSS2)inhibitors Camostat mesylate and Proxalutamide inhibit infection by blocking TMPRSS2 mediates viral membrane fusion.The main protease inhibitor Paxlovid and RNA-dependent RNA polymerase inhibitor Azvudine have been approved for treatment of COVID-19 patients.This review summarizes the current research status of neutralizing antibodies and small molecule inhibitors and prospects for their application.We expect to provide more valuable information for further studies in this field.

Latest progress in the development of anti-2019-nCoV therapeutic drugs

Status quo of domestically approved small molecule drugs against novel coronavirus and their application

Recent advances in small-molecular therapeutics for COVID-19

Recent progress of antiviral therapy for coronavirus disease 2019

Research progress in antiviral therapy for novel coronavirus pneumonia

Research and development of Chinese anti-COVID-19 drugs

COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine

Advances in research of novel coronavirus related drugs and biological products

Therapeutic strategies for COVID-19: progress and lessons learned

Current state-of-the-art and potential future therapeutic drugs against COVID-19

An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics

The Research Status of Novel Coronavirus Antibodies and Small Molecule Inhibitors

Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116)

Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)

Research Progress on Active Compounds Against Pathogenic Coronaviruses and Their Potential Target Proteins

Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19

The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs

Research Progress on Small-Molecule Drugs for Treating COVID-19

Update: Drug Treatment Options for Coronavirus Disease 2019 (COVID-19).

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

Optional Antiviral Agents for the COVID-19